Analysis of comparator selection strategies for pharmaceutical enterprises in the national reimbursement drug list access application

WANG Qingwen; AN Qin; YUAN Xiaoyan; HAN Yuzhi; CHEN Xi; WU Hongyan

doi:10.6039/j.issn.1001-0408.2026.08.03

您当前的位置：

首页 >

文章列表页 >

Analysis of comparator selection strategies for pharmaceutical enterprises in the national reimbursement drug list access application

更新时间：2026-04-24

- Analysis of comparator selection strategies for pharmaceutical enterprises in the national reimbursement drug list access application
- ZHONGGUO YAOFANG Vol. 37, Issue 8, Pages: 985-990(2026)
- 作者机构：
  
  1.贵州医科大学医药卫生管理学院，贵阳　561113
  2.贵州医科大学公共卫生与健康学院，贵阳　561113
  3.贵州民族大学法学院，贵阳　550025
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.08.03
  CLC： R95
- Received：13 January 2026，
  
  Revised：2026-03-24，
  
  Accepted：25 March 2026，
  
  Published：30 April 2026
- 稿件说明：
移动端阅览
王清文,安琴,袁小艳,等.医保准入申报中制药企业参照药品的选择策略分析 [J].中国药房,2026,37(08):985-990.

WANG Qingwen,AN Qin,YUAN Xiaoyan,et al.Analysis of comparator selection strategies for pharmaceutical enterprises in the national reimbursement drug list access application[J].ZHONGGUO YAOFANG,2026,37(08):985-990.
王清文,安琴,袁小艳,等.医保准入申报中制药企业参照药品的选择策略分析 [J].中国药房,2026,37(08):985-990. DOI： 10.6039/j.issn.1001-0408.2026.08.03.

WANG Qingwen,AN Qin,YUAN Xiaoyan,et al.Analysis of comparator selection strategies for pharmaceutical enterprises in the national reimbursement drug list access application[J].ZHONGGUO YAOFANG,2026,37(08):985-990. DOI： 10.6039/j.issn.1001-0408.2026.08.03.

摘要

目的

分析医保准入申报中制药企业参照药品的选择情况与理由，为推动企业与医保部门在该环节的沟通共识提供参考。

方法

提取国家医保局2021－2025年公布的通过形式审查的目录外药品申报材料，采用内容分析法系统梳理申报药品和参照药品的相关信息，重点分析企业选择参照药品的具体情况和理由。

结果

共收集到1 341份申报药品资料，其中1 035个（77.18%）为阳性对照、306个（22.82%）为空白对照，58个药品（4.33%）以联合用药为参照，5个药品（0.37%）以非药物（或非单纯药物）治疗方案为参照；在多个企业申报的药品中，50.00%的企业提交的参照药品存在差异。阳性对照药品的选择理由共提炼出4条基本条件和39条附加条件，空白对照药品则提炼出12条药品相关因素、2条管理因素和1条其他因素。有超过10%的药品未阐述选择参照药品的理由，选择空白对照的药品中超过44%的申报企业仅给出了1条选择理由。

结论

企业在医保准入申报中主要基于自身利益选择参照药品，其选择依据、理由阐述的充分性和规范性存在不足。建议企业遵循医保部门的原则性要求，结合自身药品特点充分、规范地说明参照药品选择理由；同时，医保部门可考虑将现有选择理由的开放式阐述形式改为封闭式填答模式，以突出选择优先级，规范企业申报行为，减少双方沟通分歧。

Abstract

OBJECTIVE

To analyze the selection and rationales of comparators for pharmaceutical enterprises in their medical insurance access application， so as to provide a reference for promoting communication and consensus between enterprises and medical insurance authorities in this process.

METHODS

The application materials for drugs outside the catalogue that passed formal review published by the National Healthcare Security Administration from 2021 to 2025 were extracted， and then content analysis was used to systematically sort out relevant information of the declared drugs and comparators； the specific situations and rationales of pharmaceutical enterprises’ selection of comparators were analyzed.

RESULTS

A total of 1 341 declared drug documents were collected. Data analysis showed that 1 035 （77.18%） were submitted with positive comparators and 306 （22.82%） used blank comparators； 58 drugs （4.33%） took combination therapy as the reference， and 5 drugs （0.37%） referred to non-pharmacological （or non-single pharmacological） treatment regimens. Among competitive drugs declared by multiple enterprises， 50.00% of the enterprises submitted different comparators. A total of 4 basic conditions and 39 additional conditions were extracted as the rationales for selecting positive comparators. For blank comparators， 12 drug-related factors， 2 administrative factors， and 1 other factor were identified. More than 10% of the drugs did not state the rationale for comparator selection， and over 44% of drugs using blank comparators provided only one justification.

CONCLUSIONS

Pharmaceutical enterprises mainly select comparators based on their own interests in the medical insurance access application， and there are deficiencies in the adequacy and standardization of their selection basis and reasoning. It is recommended that enterprises follow the principled requirements of medical insurance authorities， and fully and normatively explain the reasons for selecting comparators in combination with the characteristics of their own products. Meanwhile， it is advisable to change the current open-ended statement form of selection reasons into a closed-ended answering mode， so as to highlight the priority of selection， standardize the declaration behavior of enterprises， and reduce communication divergences between the two parties.

关键词

Keywords

references

国家医疗保障局 . 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录 [EB/OL ] .（ 2025-12-07 ） [ 2025-12-10 ] . https：//www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html .

国家医疗保障局 . 国家医疗保障局关于公布《2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》等相关文件的公告 [EB/OL ] .（ 2025-07-10 ）[ 2025-12-10 ] . https：//www.nhsa.gov.cn/art/2025/7/10/art_109_17198.html https://www.nhsa.gov.cn/art/2025/7/10/art_109_17198.html .

国家医疗保障局 . 国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整常用问答：2025年版 [EB/OL ] .（ 2025-07-10 ）[ 2025-12-10 ] . https：//www.nhsa.gov.cn/art/2025/7/10/art_109_17198.html https://www.nhsa.gov.cn/art/2025/7/10/art_109_17198.html .

国家医疗保障局 . 国家医保局发布《参照药预沟通办法（试行）》 [EB/OL ] .（ 2026-02-10 ）[ 2026-02-20 ] . https：//www.nhsa.gov.cn/art/2026/2/10/art_109_19642.html https://www.nhsa.gov.cn/art/2026/2/10/art_109_19642.html .

曹世欢，梁婉娴，张丽宁，等 . 中成药医保准入的影响因素分析 [J ] . 中国药房， 2024 ， 35 （ 22 ）： 2709 - 2715 .

国家医疗保障局 . 关于公示2021年国家医保药品目录调整通过初步形式审查药品及信息的公告 [EB/OL ] .（ 2021-07-30 ）[ 2025-12-10 ] . https：//www.nhsa.gov.cn/art/2021/7/30/art_109_6619.html https://www.nhsa.gov.cn/art/2021/7/30/art_109_6619.html .

国家医疗保障局 . 关于公示2022年国家基本医疗保险、工伤保险和生育保险药品目录调整通过初步形式审查的药品及相关信息的公告 [EB/OL ] .（ 2022-09-06 ） [ 2025-12-10 ] . https：//www.nhsa.gov.cn/art/2022/9/6/art_109_9009.html https://www.nhsa.gov.cn/art/2022/9/6/art_109_9009.html .

国家医疗保障局 . 关于公示2023年国家基本医疗保险、工伤保险和生育保险药品目录调整通过初步形式审查的药品及相关信息的公告 [EB/OL ] .（ 2023-08-18 ） [ 2025-12-10 ] . https：//www.nhsa.gov.cn/art/2023/8/18/art_109_11184.html https://www.nhsa.gov.cn/art/2023/8/18/art_109_11184.html .

国家医疗保障局 . 关于公示2024年国家基本医疗保险、工伤保险和生育保险药品目录调整通过初步形式审查的药品及相关信息的公告 [EB/OL ] .（ 2024-08-07 ） [ 2025-12-10 ] . https：//www.nhsa.gov.cn/art/2024/8/7/art_109_13499.html https://www.nhsa.gov.cn/art/2024/8/7/art_109_13499.html .

国家医疗保障局 . 关于公示通过2025年国家基本医疗保险、生育保险和工伤保险药品目录及商保创新药目录调整初步形式审查的药品及相关信息的公告 [EB/OL ] .（ 2025-08-12 ）[ 2025-12-10 ] . https：//www.nhsa.gov.cn/art/2025/8/12/art_109_17559.html https://www.nhsa.gov.cn/art/2025/8/12/art_109_17559.html .

国家医疗保障局 . 《国家医保局人力资源社会保障部关于印发〈国家基本医疗保险、工伤保险和生育保险药品目录（2022年）〉的通知》政策解读 [EB/OL ] .（ 2021-01-18 ）[ 2025-12-10 ] . https：//www.nhsa.gov.cn/art/2023/1/18/art_105_10081.html https://www.nhsa.gov.cn/art/2023/1/18/art_105_10081.html .

吴晶，刘国恩 . 中国药物经济学评价指南2025中英双语版 [M ] . 北京：中国市场出版社， 2025 ： 12 - 13 .

艾丹丹，隋宾艳，段承阿鑫，等 . 卫生技术评估中参照品遴选的国际经验与启示 [J ] . 中国新药杂志， 2023 ， 32 （ 13 ）： 1285 - 1292 .

李伟，丁锦希，施慧，等 . 优化参照药物选择机制，提高药物经济学决策利用度 [J ] . 世界临床药物， 2021 ， 42 （ 1 ）： 11 - 15 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

制药企业社会责任、员工组织承诺、员工绩效之间的关系实证研究

Related Author

ZHOU Yingbo

FENG Guozhong

WU Fang

Related Institution

No data

⁰